Lodenafil

Lodenafil

Systematic (IUPAC) name
5-(2-Ethoxy-5-{[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl}phenyl)-1-methyl-3-propyl-1,4-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
Clinical data
Trade names	Helleva
Pregnancy category	Not for use in women
Legal status	Unscheduled
Routes of administration	Oral
Identifiers
CAS Number	398507-55-6 Y
PubChem	CID: 4742795
ChemSpider	3929995 N
Chemical data
Formula	C23H32N6O5S
Molecular mass	504.602 g/mol
SMILES CCCc1c2c(c(=O)nc([nH]2)c3cc(ccc3OCC)S(=O)(=O)N4CCN(CC4)CCO)n(n1)C
InChI InChI=1S/C23H32N6O5S/c1-4-6-18-20-21(27(3)26-18)23(31)25-22(24-20)17-15-16(7-8-19(17)34-5-2)35(32,33)29-11-9-28(10-12-29)13-14-30/h7-8,15,30H,4-6,9-14H2,1-3H3,(H,24,25,31) Key:NEYKRKVLEWKOBI-UHFFFAOYSA-N
NY (what is this?)  (verify)

Lodenafil (Hydroxyhomosildenafil, trade name Helleva) is a drug belonging to a class of drugs called PDE5 inhibitor, which many other erectile dysfunction drugs such as sildenafil, tadalafil, and vardenafil also belong to. Like udenafil and avanafil it belongs to a new generation of PDE5 inhibitors.

Lodenafil is formulated as a prodrug in the form of the carbonate ester dimer, lodenafil carbonate, which breaks down in the body to form two molecules of the active drug lodenafil. This formulation has higher oral bioavailability than the parent drug.

It is manufactured by Cristália Produtos Químicos e Farmacêuticos in Brazil and sold there under the brand-name Helleva.

It has undergone Phase III clinical trials, but is not yet approved for use in the United States by the U.S. Food and Drug Administration.

See also

Homosildenafil